1. Home
  2. Medical Research
  3. Palo Alto, CA
  4. A Foundation Building Strength

A Foundation Building Strength

A Foundation Building Strength is ranked among medical research organizations in Palo Alto, CA, with an America's Best Score of 89 out of 100, based on its 2024 Form 990.

  • Palo Alto, CA
  • Tax-exempt since 2008
  • EIN: 26-1761329
buildingstrength.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate
89OF 100 Ranked in Palo Alto Medical Research How this score is calculated

Organization summary

A Foundation Building Strength is a 501(c)(3) organization, classified under Medical Research (NTEE H12). Contributions are tax-deductible.

3825 El Camino Real, Palo Alto, CA 94306-3324

Among the 5 scored medical research organizations in Palo Alto, A Foundation Building Strength holds 33.3 months of operating reserves (peer median 14.6 months), runs a typical yearly surplus of 61.1% (peers: surplus of 29.0%), and has grown spending 23.3% a year (peers: grown spending 3.5% a year).

In fiscal year 2024 it reported $1,048,763 in revenue and $1,163,106 in expenses, with contributions making up 90.6% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2024 Form 990

To find treatments for Nemaline Myopathy

Main program · fiscal year 2024

  • The largest program services include research grants to foreign and domestic organizations advancing Nemaline Myopathy science. Domestically, grants supported the development of gene therapy for ACTA1-based Nemaline Myopathy; gene replacement and drug screening studies for KLHL40-, KLHL41-related forms; creation of patient-derived 3D muscle models to test potential treatments; maintenance of a nat… Read more

    The largest program services include research grants to foreign and domestic organizations advancing Nemaline Myopathy science. Domestically, grants supported the development of gene therapy for ACTA1-based Nemaline Myopathy; gene replacement and drug screening studies for KLHL40-, KLHL41-related forms; creation of patient-derived 3D muscle models to test potential treatments; maintenance of a national biobank to advance research and clinical trial readiness; and development of soft robotic garments to assist lower-limb movement and improve mobility for children with NM. Internationally, grants supported research to test therapies for KBTBD13-related Nemaline Myopathy (NEM6) using a mouse model to determine treatment timing and efficacy in preventing or reversing disease progression.

    $1,042,113 spent

Where each dollar went · fiscal year 2024

Of every dollar it spent, 90¢ went to programs, 3¢ to management and 7¢ to fundraising.

  • Programs $1,042,113
  • Management $44,854
  • Fundraising $76,139

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

America's Best Score

Free assessmentMethodology
Score89 / 100
DesignationRanked

Score breakdown

MeasureThis organizationPoints
Operating reserves33.3 months23.1 / 25
Financial balance (median margin)+61.1%13.4 / 20
Transparency3 full 990s, latest TY202420 / 20
Program growth+23.3% / yr15 / 15
Track record18 years7.2 / 10
Debt load3.8% of assets10 / 10
Total88.8 → 89

Compared with Palo Alto peers

MeasureThis organizationPeer median
Operating reserves33.3 mo14.6 mo
Typical margin+61.1%+29.0%
Spending growth+23.3% / yr+3.5% / yr
Debt load3.8%45.4%

Peers: the 5 Palo Alto medical research organizations with a score, ranked or below the bar.

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$1,048,763Fiscal year 20242022: $1,839,49220222023: $1,461,42820232024: $1,048,7632024
Expenses$1,163,106Fiscal year 20242022: $765,56820222023: $907,01220232024: $1,163,1062024
Total assets$3,358,607Fiscal year 20242022: $2,925,12020222023: $3,531,62420232024: $3,358,6072024
Total liabilities$128,832Fiscal year 20242022: $133,52420222023: $185,61220232024: $128,8322024
Fiscal year ending December 2024
Revenue$1,048,763
Expenses$1,163,106
Net income−$114,343
Net assets$3,229,775

Notable sources of revenue

Percent of total revenue
Contributions$950,307
Program services$0
Investment income$110,613
Other (net)−$12,157

Assets / debt

Total assets$3,358,607
Total liabilities$128,832
Net assets$3,229,775

Compensation

Not in our extract for this year.

Fiscal year ending December 2023
Revenue$1,461,428
Expenses$907,012
Net income$554,416
Net assets$3,346,012

Notable sources of revenue

Percent of total revenue
Contributions$1,269,206
Program services$0
Investment income$51,267
Other (net)$140,955

Assets / debt

Total assets$3,531,624
Total liabilities$185,612
Net assets$3,346,012

Compensation

Not in our extract for this year.

Fiscal year ending December 2022
Revenue$1,839,492
Expenses$765,568
Net income$1,073,924
Net assets$2,791,596

Notable sources of revenue

Percent of total revenue
Contributions$1,741,351
Program services$0
Investment income$4,713
Other (net)$93,428

Assets / debt

Total assets$2,925,120
Total liabilities$133,524
Net assets$2,791,596

Compensation

Officers and key employees$0
Share of expenses0.0%

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?